ANDA 200166, held by Azurity. Amphetamine Sulfate.
As of Nov 16, 2026, ANDA 200166 (Evekeo), held by Azurity, was first approved by FDA on Aug 9, 2012, with 5 approved supplements and 0 published complete response letters.
INDICATIONS AND USAGE Amphetamine Sulfate Tablets, USP, are indicated for: Narcolepsy Attention Deficit Disorder with Hyperactivity as an integral part of a total treatment program which typically includes other remedial measures (psychological, educational, social) for a stabilizing effect in children with behavioral syndrome characterized by the following group of developmentally inappropriate symptoms: moderate to severe distractibility, short attention span, hyperactivity, emotional lability, and impulsivity. The diagnosis of the syndrome should not be made with finality when these symptoms are only of comparatively recent origin.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Aug 9, 2012 | Original application | Approved | None posted |
| Evekeo5MG · tablet;oral | Amphetamine Sulfate | Rx |
| Evekeo10MG · tablet;oral | Amphetamine Sulfate | Rx |
| Oct 13, 2023 | Supplement 10Labeling · Standard review | Approved | None posted |
| Feb 25, 2022 | Supplement 9Labeling · Standard review | Approved | None posted |
| Jan 4, 2017 | Supplement 5Labeling · Standard review | Approved | None posted |
| Apr 17, 2015 | Supplement 3Labeling · Standard review | Approved | None posted |
| Sep 12, 2014 | Supplement 2Labeling · Standard review | Approved | None posted |
| Aug 9, 2012 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters